Prosecution Insights
Last updated: May 29, 2026
Application No. 18/194,805

GOLD NONOCLUSTERS, DOPAMINE BIOSENSORS INCLUDING THEM, AND METHODS FOR DIAGNOSING NEUROLOGICAL DISEASES USING THE SAME

Non-Final OA §102
Filed
Apr 03, 2023
Priority
Apr 04, 2022 — RE 10-2022-0041733 +1 more
Examiner
BAKSHI, PANCHAM
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Industry-Academic Cooperation Foundation Yonsei University
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
882 granted / 1146 resolved
+17.0% vs TC avg
Strong +30% interview lift
Without
With
+30.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
45 currently pending
Career history
1220
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
42.1%
+2.1% vs TC avg
§102
12.8%
-27.2% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1146 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Claims 1-14 are pending. Election/Restrictions Applicant's election without traverse of Group I, claims 1-5, directed to gold nanocluster of formula I, and the species: PNG media_image1.png 358 916 media_image1.png Greyscale in the reply filed on 12/29/2025 is acknowledged. The election was made without traverse. The requirement is therefore made FINAL. Claims 6-14 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i). Claims 1-5 are under current examination. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-5 and elected species are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Lee (KR102172084, published 10/30/2020; Machine English translation is used for this rejection). Lee discloses gold nanocluster of formula 1, with same x, y, L1, R1 and R2 along with the synthesis, which is same as described in the instant specification and elected species with x=22, Y=18, same L1, R1 and R2 along with synthesis of elected species (entire patent, specifically examples): PNG media_image2.png 735 943 media_image2.png Greyscale PNG media_image3.png 638 945 media_image3.png Greyscale PNG media_image4.png 748 953 media_image4.png Greyscale PNG media_image5.png 704 968 media_image5.png Greyscale Since the cited prior teaches all of the limitations of the instant claims 1-5, these claims are anticipated. Conclusion No Claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PANCHAM BAKSHI whose telephone number is (571)270-3463. The examiner can normally be reached M-Thu 7-4.30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Milligan Adam can be reached at 571-2707674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PANCHAM BAKSHI/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Apr 03, 2023
Application Filed
Mar 12, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637407
Process For The Preparation of Mixed Polyol-Carboxylic Acid EstersE
2y 10m to grant Granted May 26, 2026
Patent 12630569
METHOD FOR PRODUCING ORGANIC SILICON COMPOUND HAVING KETIMINE STRUCTURE
3y 8m to grant Granted May 19, 2026
Patent 12617748
A PROCESS FOR RECYCLING OF POLYETHYLENE TEREPHTHALATE (PET) WASTE
2y 11m to grant Granted May 05, 2026
Patent 12612385
COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS
2y 5m to grant Granted Apr 28, 2026
Patent 12595353
PLASTICIZER COMPOSITION AND RESIN COMPOSITION COMPRISING THE SAME
3y 0m to grant Granted Apr 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+30.1%)
2y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1146 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month